Influence of cytomegalovirus (CMV) sero-positivity on CMV infection, lymphocyte recovery and non-CMV infections following T-cell-depleted allogeneic stem cell transplantation: A comparison between two T-cell depletion regimens

Bone Marrow Transplantation

Volumn 33, Issue 2, 2004, Pages 197-204

  Chakrabarti, Suparno ^a,b,c   Milligan, D W ^b   Brown, J ^a   Osman, H ^b   Vipond, I B ^a   Pamphilon, D H ^a   Marks, D I ^a  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Campath IH; CD34+selection; Cytomegalovirus; T cell depletion

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTIVIRUS AGENT; BUSULFAN; CD34 ANTIGEN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; ITRACONAZOLE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; INCUBATION TIME; INFECTION RISK; INTERMETHOD COMPARISON; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROBABILITY; RECURRENT DISEASE; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS REACTIVATION;

ADOPTIVE TRANSFER; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODIES, VIRAL; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; RECURRENCE; SURVIVAL RATE; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING;

EID: 0842345615     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704334     Document Type: Article

References (38)

1. Li CR, Greenberg PD, Gilbert MJ et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971-1979.
2. Nguyen Q, Champlin R, Giralt S et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow recipients. Clin Infect Dis 1999; 28: 618-623.
3. Einsele H, Hebart H, Kauffmann-Schneider C et al. Risk factors for treatment failures in patients receiving PCR-based pre-emptive therapy for CMV infection. Bone Marrow Transplant 2000; 25: 757-763.
4. Ljungman P. Prevention and treatment of viral infections in stem cell transplant recipients. Br J Haematol 2002; 118: 44-57.
5. Ljungman P, Deliliers GL, Platzbecker U et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001; 97: 388-392.
6. Cwynarski K, Ainsworth J, Cobbold M et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001; 97: 1232-1240.
7. Einsele H, Roosnek E, Rufer N et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99: 3916-3922.
8. Broers AE, van Der Holt R, van Essen JW et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000; 95: 2240-2245.
9. Craddock C, Szydlo RM, Dazzi F et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol 2000; 112: 228-236.
10. Kroger N, Zabelina T, Kruger W et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Haematol 2001; 113: 1060-1071.
11. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478-488.
12. Przepiorka D, Ippoliti C, Panina A et al. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplant 1994; 13: 461-464.
13. Couriel D, Canosa J, Engler H et al. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplant 1996; 18: 1347-353.
14. Hertenstein B, Hampl W, Bunjes D et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant 1995; 15: 387-393.
15. Martino R, Rovira M, Carreras E et al. The AlloPBSCT and Infectious/Non-infectious Complications Subcommittes of the Grupo Espanol de Trasplante Hematopoyetico (GETH). Severe infections after allogeneic peripheral blood stem cell transplantation: a matched-pair comparison of unmanipulated and CD34+ cell-selected transplantation. Haematologica 2001; 86: 1075-1086.
16. Hebart H, Brugger W, Grigoleit U et al. Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based pre-emptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality. Blood 2001; 97: 2183-2185.
17. Chakrabarti S, Brown J, Guttridge M et al. Early lymphocyte recovery is an important determinant of outcome following allogeneic transplantation with CD34+ selected graft and limited T cell addback. Bone Marrow Transplant 2003; 32: 23-30.
18. Chakrabarti S, MacDonald D, Hale G et al. T cell depletion with Campath-1H 'in the bag' for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br J Haematol 2003; 121: 109-118.
19. Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357-4363.
20. Chakrabarti S, Collingham KE, Fegan CD et al. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections. Bone Marrow Transplant 2001; 28: 759-763.
21. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
22. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
23. Hale G. The CD52 antigen and development of the CAM-PATH antibodies. Cytotherapy 2001; 3: 137-143.
24. Small TN, Papadopoulos EB, Boulad F et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999; 93: 467-480.
25. Rebello P, Cwynarsky K, Varughese M et al. Pharmacokinetics of Campath-1H in bone marrow transplant patients. Cytotherapy 2002; 3: 261-267.
26. Chakrabarti S, Mautner V, Osman H et al. Adenovirus infections following allogeneic stem cell transplantation: the incidence and outcome in relation to graft manipulation, immunosuppression and immune recovery. Blood 2002; 100: 1619-1627.
27. Chakrabarti S, Collingham KE, Marshall T et al. Respiratory virus infections in adult T cell-depleted transplant recipients: the role of cellular immunity. Transplantation 2001; 72: 1460-1463.
28. Chakrabarti S, Osman H, Collingham K et al. Polyoma viruria in stem cell transplant recipients T cell depleted with Campath-1H: the incidence and outcome in relation to graft manipulation, donor type and conditioning. Bone Marrow Transplant 2003; 31: 379-386.
29. Chakraverty R, Robinson S, Peggs K et al. Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation. Bone Marrow Transplant 2001; 28: 827-834.
30. Grob JP, Grundy JE, Prentice HG et al. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections. Lancet 1987; 1: 774-776.
31. Lin TS, Zahrieh D, Weller E et al. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation. Transplantation 2002; 74: 49-54.
32. Einsele H, Ehninger G, Hebart H et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-2820.
33. Reusser P, Einsele H, Lee J et al. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Randomized multicenter trial of foscarnet versus ganciclovir for pre-emptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99: 1159-1164.
34. Williamson EC, Millar MR, Steward CG et al. Infections in adults undergoing unrelated donor bone marrow transplantation. Br J Haematol 1999; 104: 560-568.
35. Marr KA, Carter RA, Boeckh M et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366.
36. Grigoleit GU, Riegler S, Hebart H et al. Human cytomegalovirus induces a direct inhibitory effect on antigen presentation by monocytes-derived immature dendritic cells. Bone Marrow Transplant 2002; 29 (Suppl.): S32.
37. Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 1993; 118: 179-184.
38. Ljungman P, Brand R, Einsele H et al. Donor CMV serological status influences the outcome after unrelated donor stem cell transplantation; an EBMT Megafile analysis. Bone Marrow Transplant 2002; 29 (Suppl.): S32.